Glaxosmithkline Llc Drug Patent Portfolio

Glaxosmithkline Llc owns 6 orange book drugs protected by 11 US patents with Lamictal Cd having the least patent protection, holding only 1 patent. And Lamictal Odt with maximum patent protection, holding 3 patents. Given below is the list of Glaxosmithkline Llc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7919115 Orally disintegrating tablet compositions of lamotrigine 04 Jan, 2029
Active
US8840925 Orally disintegrating tablet compositions of lamotrigine 02 Jul, 2028
Active
US9339504 Orally disintegrating tablet compositions of lamotrigine 02 Jul, 2028
Active
US8637512 Formulations and method of treatment 14 Jun, 2028
Active
US9144547 Oral dosage form for controlled drug release 22 Sep, 2023 Expired
US7927624 Hydrophilic/lipophilic polymeric matrix dosage formulation 02 Dec, 2021 Expired
US8303986 Hydrophilic/lipophilic polymeric matrix dosage formulation 12 Apr, 2021 Expired
US6649659 Atovaquone pharmaceutical compositions 10 Jan, 2017 Expired
US6649659 Atovaquone pharmaceutical compositions 10 Jul, 2016 Expired
US5681588 Delayed release microtablet of β-phenylpropiophenone derivatives 28 Oct, 2014 Expired
US5698226 Water-dispersible tablets 29 Jul, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Glaxosmithkline Llc.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 24 Jun, 2024 US8303986
Expire Patent 22 May, 2023 US7927624
Expire Patent 08 May, 2023 US7919115 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 22 Feb, 2023 US9144547
Maintenance Fee Reminder Mailed 05 Dec, 2022 US7927624
Maintenance Fee Reminder Mailed 21 Nov, 2022 US7919115 (Litigated)
Email Notification 27 Apr, 2022 US7919115 (Litigated)
Mail PUB other miscellaneous communication to applicant 25 Apr, 2022 US7919115 (Litigated)
PUB Other miscellaneous communication to applicant 21 Apr, 2022 US7919115 (Litigated)
Letter of Express Abandonment Filed 18 Apr, 2022 US7919115 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 21 Apr, 2020 US8303986
Payment of Maintenance Fee, 4th Year, Large Entity 14 Feb, 2019 US9144547
Payment of Maintenance Fee, 8th Year, Large Entity 09 Oct, 2018 US7927624
Payment of Maintenance Fee, 8th Year, Large Entity 05 Oct, 2018 US7919115 (Litigated)
Patent Issue Date Used in PTA Calculation 29 Sep, 2015 US9144547


Glaxosmithkline Llc's Drug Patent Litigations

Glaxosmithkline Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 25, 2002, against patent number US6649659. The petitioner , challenged the validity of this patent, with DEARN as the respondent. Click below to track the latest information on how companies are challenging Glaxosmithkline Llc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6649659 April, 2002 Decision
(30 Jun, 2003)
DEARN


Glaxosmithkline Llc's Family Patents

Glaxosmithkline Llc drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 10.7% of its total global patent coverage. 10 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Glaxosmithkline Llc Drug List

Given below is the complete list of Glaxosmithkline Llc's drugs and the patents protecting them.


1. Lamictal Cd

Lamictal Cd is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5698226
(Pediatric)
Water-dispersible tablets 29 Jul, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lamictal Cd's drug page


2. Lamictal Odt

Lamictal Odt is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7919115 Orally disintegrating tablet compositions of lamotrigine 04 Jan, 2029
(4 years from now)
Active
US8840925 Orally disintegrating tablet compositions of lamotrigine 02 Jul, 2028
(3 years from now)
Active
US9339504 Orally disintegrating tablet compositions of lamotrigine 02 Jul, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lamictal Odt's drug page


3. Lamictal Xr

Lamictal Xr is protected by 2 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8637512 Formulations and method of treatment 14 Jun, 2028
(3 years from now)
Active
US9144547 Oral dosage form for controlled drug release 22 Sep, 2023
(1 year, 21 days ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lamictal Xr's drug page


4. Mepron

Mepron is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6649659
(Pediatric)
Atovaquone pharmaceutical compositions 10 Jan, 2017
(7 years ago)
Expired
US6649659 Atovaquone pharmaceutical compositions 10 Jul, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mepron's drug page


5. Requip Xl

Requip Xl is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7927624 Hydrophilic/lipophilic polymeric matrix dosage formulation 02 Dec, 2021
(2 years ago)
Expired
US8303986 Hydrophilic/lipophilic polymeric matrix dosage formulation 12 Apr, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Requip Xl's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Rythmol Sr

Rythmol Sr is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5681588 Delayed release microtablet of β-phenylpropiophenone derivatives 28 Oct, 2014
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rythmol Sr's drug page


Glaxosmithkline Llc News

GSK stock sees significant increase following $2.2 billion Zantac lawsuit settlement

10 Oct, 2024

GSK's new asthma medication significantly reduced attacks in late-stage study

09 Sep, 2024

Trial shows that GSK's antibody drug decreases the frequency of COPD attacks - Yahoo Finance

06 Sep, 2024

GSK's medication for asthma, Nucala, achieves success in Phase III trial for COPD - Yahoo Finance

06 Sep, 2024

See More